Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Other Non-Current Liabilities data on record, last reported at $500000.0 in Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities fell 54.09% year-over-year to $500000.0; the TTM value through Jun 2025 reached $500000.0, down 54.09%, while the annual FY2024 figure was $849000.0, 52.3% down from the prior year.
  • Other Non-Current Liabilities reached $500000.0 in Q2 2025 per ZNTL's latest filing, down from $849000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $45.0 million in Q1 2022 and bottomed at $500000.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 4 years is $6.2 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 96.02% in 2023, then skyrocketed 117.8% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $2.6 million in 2022, then plummeted by 32.06% to $1.8 million in 2023, then tumbled by 52.3% to $849000.0 in 2024, then tumbled by 41.11% to $500000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $500000.0 in Q2 2025, $849000.0 in Q4 2024, and $1.1 million in Q2 2024.